Viral Genetics Inc. announced that it has submitted a pre-IND briefing document to the U.S. Food and Drug Administration (FDA) for its Lyme Disease drug candidate, VGV-L, marking important milestones for both the Company and its supporters in the Lyme community. The pre-IND submission provides extensive research information gathered by Viral Genetics' researchers over a 2 [1/2] year period of rigorous and detailed testing which resulted in positive results, to the FDA, along with a protocol for a proposed U.S. human clinical trial designed under the guidance of Lyme clinician at one of the nation's top medical centers. The company anticipates that the response to the pre-IND submission will be received in March-April 2012.